Confronto

CagriSema vs. Eloralintide

Due peptidi a confronto — identità, base di evidenze, stato legale ed eventi avversi noti.

Identità

Categoria

Metabolico

N. CAS

nessun dato

Peso molecolare

nessun dato

Emivita

nessun dato

Sequenza

nessun dato

Meccanismo d'azione

CagriSema

CagriSema combines two satiety pathways in one weekly injection: the amylin analogue cagrilintide and the GLP-1 agonist semaglutide. Both suppress appetite and food intake — together more than either component alone.

Eloralintide

Eloralintide selectively activates amylin receptors (preferentially AMY1R) and promotes satiety. The approach targets weight loss via the amylin axis, complementary to or independent of GLP-1 agents.

Base di evidenze

Evidenza più alta

RCT sull'uomo

Studi

di cui sull'uomo

Effetti registrati

Contraddizioni aperte

Eventi avversi documentati

Stato legale

Country	CagriSema	Eloralintide
Germania	Non approvato	Non approvato
Stati Uniti	Non approvato	Non approvato

Voci complete

Frequently asked questions

What is the difference between CagriSema and Eloralintide?: CagriSema is classified as "Metabolico", while Eloralintide is classified as "Metabolico". CagriSema: CagriSema is a fixed-dose combination of the amylin analogue cagrilintide and the GLP-1 agonist semaglutide (Novo Nordisk), in late-stage development for obesity and type 2 diabetes. Eloralintide: Eloralintide is a selective, long-acting amylin receptor agonist from Eli Lilly for once-weekly subcutaneous use — under investigation for obesity, alone and combined with incretin therapy. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
Which peptide is better supported by science, CagriSema or Eloralintide?: The highest available evidence level is "RCT sull'uomo" for CagriSema and "RCT sull'uomo" for Eloralintide. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
What is the legal status of CagriSema and Eloralintide in Germany and the United States?: Germania: CagriSema — Non approvato, Eloralintide — Non approvato. Stati Uniti: CagriSema — Non approvato, Eloralintide — Non approvato. These are factual summaries with source and review date on the individual pages.

Country

CagriSema

Eloralintide

Germania

Non approvato

Stati Uniti

Non approvato

Frequently asked questions

What is the difference between CagriSema and Eloralintide?

CagriSema is classified as "Metabolico", while Eloralintide is classified as "Metabolico". CagriSema: CagriSema is a fixed-dose combination of the amylin analogue cagrilintide and the GLP-1 agonist semaglutide (Novo Nordisk), in late-stage development for obesity and type 2 diabetes. Eloralintide: Eloralintide is a selective, long-acting amylin receptor agonist from Eli Lilly for once-weekly subcutaneous use — under investigation for obesity, alone and combined with incretin therapy. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.

Which peptide is better supported by science, CagriSema or Eloralintide?

The highest available evidence level is "RCT sull'uomo" for CagriSema and "RCT sull'uomo" for Eloralintide. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.

What is the legal status of CagriSema and Eloralintide in Germany and the United States?

Germania: CagriSema — Non approvato, Eloralintide — Non approvato. Stati Uniti: CagriSema — Non approvato, Eloralintide — Non approvato. These are factual summaries with source and review date on the individual pages.